

Title	CALR mutation profile in Irish patients with myeloproliferative neoplasms
Authors	Haslam, Karl;Conneally, Eibhlin;Flynn, Catherine M.;Cahill, Mary R.;Gilligan, Oonagh;O'Shea, Derville;Langabeer, Stephen E.
Publication date	2016-06-23
Original Citation	Haslam, K., Conneally, E., Flynn, C. M., Cahill, M. R., Gilligan, O., O'Shea, D. and Langabeer, S. E. (2016) 'CALR mutation profile in Irish patients with myeloproliferative neoplasms', Hematology/ Oncology and Stem Cell Therapy, 9(3), pp. 112-115. doi:10.1016/j.hemonc.2016.05.002
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1016/j.hemonc.2016.05.002
Rights	© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). - http://creativecommons.org/licenses/by-nc-nd/4.0/
Download date	2026-08-30 18:49:59
Item downloaded from	https://hdl.handle.net/10468/3391



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh



Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/hemonc



BRIEF COMMUNICATION

CALR mutation profile in Irish patients with myeloproliferative neoplasms



Karl Haslam^a, Eibhlin Conneally^b, Catherine M. Flynn^b, Mary R. Cahill^c,
Oonagh Gilligan^c, Derville O'Shea^c, Stephen E. Langabeer^{a,*}

^a Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland

^b Department of Haematology, St. James's Hospital, Dublin, Ireland

^c Department of Haematology, Cork University Hospital, Cork, Ireland

Received 4 April 2016; accepted 31 May 2016

Available online 23 June 2016

KEYWORDS

CALR;
Essential thrombocythemia;
JAK2;
Myeloproliferative neoplasm;
Primary myelofibrosis

Abstract

Insertion and/or deletion mutations of the *CALR* gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of *CALR* mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of *CALR* mutations. *CALR* mutations were detected in 58 patients. Type 1 and Type 1-like deletion mutations were the most common ($n = 40$) followed by Type 2 and Type 2-like insertion mutations ($n = 17$). The *CALR* mutation profile in Irish ET and PMF patients appears similar to that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will improve clinical management.

© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) comprise the clinically and pathologically related polycythemia vera (PV), essential

* Corresponding author at: Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James's Hospital, James's Street, Dublin 8, Ireland.

E-mail address: slangabeer@stjames.ie (S.E. Langabeer).

thrombocythemia (ET), and primary myelofibrosis (PMF). These diseases are characterized by an over production of mature hematopoietic cells, extramedullary hematopoiesis, and clinically by a tendency for thrombosis, hemorrhage, and a potential to transform into acute leukemia. While almost all PV patients are characterized by the Exon 14 *JAK2* V617F and Exon 12 mutations, until recently, the only known driver mutations of ET and PMF were the *JAK2* V617F and *MPL* Exon 10 mutations present in up to two-thirds of patients. The landmark discovery of insertion and/or deletion (indel) *CALR* Exon 9 mutations in 60–80% of *JAK2* V617F- and *MPL* Exon 10-negative ET and PMF cases compels the inclusion of *CALR* mutation analysis into the molecular diagnostic algorithm for these MPNs. The two common *CALR* mutations are the Type 1 52-bp deletion (p.L367fs*46) and the Type 2 5-bp insertion (p.K385fs*47), which account for more than 85% of indels [1,2] with most other mutations being Type 1-like deletions or Type 2-like insertions. *CALR* mutations are thought to exert their function by perturbation of the intracellular Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway by activation of *MPL* [3]. Molecular analysis of these three driver mutation types is likely to be a major criterion in the next revision of the World Health Organization classification of hematopoietic tumors [4]. Aside from their diagnostic importance, it is becoming increasingly apparent that the different types of *CALR* mutations impart prognostic information about thrombotic potential and leukemic transformation [5–7]. Furthermore, some geographical heterogeneity exists in both the frequency and profile of *CALR* mutations in ET and PMF when considering patients from North America [8,9], Europe [1,2,10,11], Central and South America [12,13], India [14], and Far East Asia [15,16].

Given the importance of *CALR* mutational analysis in the diagnosis and prognosis of ET and PMF, the pattern of *CALR* mutations was investigated in a cohort of adult Irish patients with MPN. These data are likely to provide information about how to efficiently incorporate *CALR* mutation analysis into a prospective MPN molecular diagnostic service.

Materials and methods

A series of 202 confirmed and suspected MPN cases from two large Irish hematology centers were subjected to retrospective *CALR* mutational analysis. None of the patients had evidence of the *JAK2* V617F mutation by allele-specific polymerase chain reaction (PCR) [17]. *CALR* mutations were detected in archival genomic DNA from peripheral blood

(*n* = 190) or bone marrow (*n* = 12) by fluorescent PCR followed by fragment length analysis. The *CALR* assay has been previously demonstrated to possess a detection sensitivity of ~1% mutant allele burden [18].

Results

CALR mutations were detected in 58 patients (30 female and 28 male) with a median age of 56 years (range, 25–86 years) in whom the diagnosis was ET (*n* = 45), PMF (*n* = 10), post-ET myelofibrosis (*n* = 2), and myelodysplastic/MPNs (*n* = 1). Type 1 *CALR* mutations were the most prevalent, (*n* = 35) followed by Type 2 mutations (*n* = 16; Table 1). Of the remaining seven cases, five had Type 1-like deletions, one had a Type 2-like insertion, and one previously described patient harbored two mutated clones [19]. The distribution of these mutations in the MPN subtypes is given in Table 1.

Discussion

The description of *CALR* Exon 9 mutations in ET and PMF patients has changed the molecular diagnostic algorithm for MPN as they are now considered the second most common type of driver mutations in ET and PMF cases. Provision of a confirmatory molecular diagnosis in a significantly higher number of patients will enhance risk stratification and allows for appropriate treatment: retrospective screening has demonstrated the efficacy of existing therapeutic modalities such as interferon-alpha and JAK inhibitors in *CALR*-mutated MPN patients [20,21].

Because of the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical and ethnic variation previously reported, the incidence of *CALR* indels was investigated in a retrospective cohort of Irish MPN patients to determine the existing mutational spectrum. Given the near mutual exclusivity of the *JAK2* V617F and *CALR* mutations but acknowledging the rarity of these mutations co-existing in ET and a report of *CALR* mutations in *JAK2*-negative PV [22–24], this retrospective study was limited to known and suspected ET and PMF patients in whom the *JAK2* V617F was previously undetected. Although a number of methodological approaches exist to detect *CALR* mutations [25], the sensitivity of the fragment length analysis used in this study was deemed sufficient to detect clinically relevant mutations: *CALR* mutant allele burdens are usually much higher [26].

Table 1 Incidence of *CALR* Mutations in Irish MPN Patients

	Type 1	Type 1 like	Type 2	Type 2 like	Other
ET (<i>n</i> = 45)	26	5	12	1	1
PMF (<i>n</i> = 10)	8	0	2	0	0
Post-ET MF (<i>n</i> = 2)	1	0	1	0	0
MDS/MPN (<i>n</i> = 1)	0	0	1	0	0
Total	35 (60.3%)	5 (8.6%)	16 (27.6%)	1 (1.7%)	1 (1.7%)

Note: ET = essential thrombocythemia; MDS/MPN = myelodysplastic/myeloproliferative neoplasm; MF = myelofibrosis; PMF = primary myelofibrosis.

The *CALR* mutation profile and frequency in this cohort of Irish patients are broadly in line with that of other series from Europe and North America, with Type 1 and Type 1-like mutations being more prevalent than Type 2 and Type 2-like in both ET and PMF patients. Establishing this mutational profile allows considered incorporation of *CALR* mutation testing into a prospective MPN molecular diagnostic algorithm so as to optimize the number of patients who would benefit from such testing within existing laboratory resources. Given the previously described variability in requesting *JAK2* V617F analysis within this country [27], together with the knowledge of the near absence of *CALR* mutations in splanchic, cerebral, and other cases of unprovoked venous thrombosis [28–30], limiting testing to those patients with suspected ET and PMF appears judicious.

In conclusion, the incidence and spectrum of *CALR* mutations in Irish MPN patients are similar to those of other European cohorts confirming these driver mutations as the second most frequently observed in ET and PMF. This knowledge allows the effective incorporation of *CALR* mutation analysis into a prospective testing algorithm, thus enabling an enhanced diagnosis and improved clinical management.

Conflicts of interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013;369:2379–90.
- [2] Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic *CALR* mutations in myeloproliferative neoplasms with nonmutated *JAK2*. *N Engl J Med* 2013;369:2391–405.
- [3] Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. *Blood* 2016;127:1325–35.
- [4] Barbui T, Thiele H, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. *Blood Cancer J* 2015;5:e337.
- [5] Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *Am J Hematol* 2014;89: E121–E4.
- [6] Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like *CALR* mutations in myelofibrosis. *Blood Cancer J* 2015;5:e360.
- [7] Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanese C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in *CALR*-mutant myeloproliferative neoplasms. *Leukemia* 2016;30:431–8.
- [8] Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. *CALR* vs *JAK2* vs *MPL*-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. *Leukemia* 2014;28:1472–7.
- [9] Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, et al. Clinical validation of a multipurpose assay for detection and genotyping of *CALR* mutations in myeloproliferative neoplasms. *Am J Clin Pathol* 2015;144:746–55.
- [10] Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, et al. Next-generation deep-sequencing detects multiple clones of *CALR* mutations in patients with BCR-ABL1 negative MPN. *Leukemia* 2016;30:973–6.
- [11] Grinsztejn E, Percy MJ, McClenaghan D, Quintana M, Cuthbert RJ, McMullin MF. The prevalence of *CALR* mutations in a cohort of patients with myeloproliferative neoplasms. *Int J Lab Hematol* 2016;38:102–6.
- [12] Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, Colunga-Pedraza P, Guzman-Olvera V, Reyes-Núñez V, et al. The mutation profile of *JAK2*, *MPL* and *CALR* in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. *Hematol Oncol Stem Cell Ther* 2015;8: 16–21.
- [13] Nunes DP, Lima LT, Chauffaille Mde L, Mitne-Neto M, Santos MT, Cliquet MG, et al. *CALR* mutations screening in wild type *JAK2*(V617F) and *MPL*(W515K/L) Brazilian myeloproliferative neoplasm patients. *Blood Cells Mol Dis* 2015;55: 236–40.
- [14] Sazawal S, Singh N, Mahapatra M, Saxena R. Calreticulin mutation profile in Indian patients with primary myelofibrosis. *Hematology* 2015;20:567–70.
- [15] Li B, Xu J, Wang J, Gale RP, Xu Z, Cui Y, et al. Calreticulin mutations in Chinese with primary myelofibrosis. *Haematologica* 2014;99:1697–700.
- [16] Shirane S, Araki M, Morishita S, Eda Hiro Y, Takei H, Yoo Y, et al. *JAK2*, *CALR*, and *MPL* mutation spectrum in Japanese patients with myeloproliferative neoplasms. *Haematologica* 2015;100, e46–e8.
- [17] Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase *JAK2* in human myeloproliferative disorders. *Lancet* 2005;365:1054–61.
- [18] Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E. Assessment of *CALR* mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. *Br J Haematol* 2014; 66:800–2.
- [19] Haslam K, Conneally E, Langabeer SE. Capricious *CALR* mutated clones in myeloproliferative neoplasms. *Blood Cells Mol Dis* 2016;57:110–1.
- [20] Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon- α therapy in essential thrombocythemia patients with *CALR* mutations. *Blood* 2015;126:2585–91.
- [21] Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A, et al. Ruxolitinib is an effective treatment for *CALR*-positive patients with myelofibrosis. *Br J Haematol* 2016;173:938–40.
- [22] Broséus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in *JAK2*-negative polycythemia vera. *Blood* 2014;124:3964–6.
- [23] McGaffin G, Harper K, Stirling D, McLintock L. *JAK2* V617F and *CALR* mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. *Br J Haematol* 2014;167:276–8.
- [24] Mansier O, Migeon M, Etienne G, Bidet A, Lippert E. *JAK2*V617F and *CALR* double mutations are more frequently encountered in patients with low *JAK2*V617F allelic burdens. *Leuk Lymphoma* 2016 (in press).
- [25] Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, et al. Molecular diagnostics of myeloproliferative neoplasms. *Eur J Haematol* 2015;95:270–9.
- [26] Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, et al. Evaluation of methods to detect *CALR* mutations in myeloproliferative neoplasms. *Leuk Res* 2015;39:82–7.

- [27] Langabeer SE. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm. *J Clin Pathol* 2012;65:1149–50.
- [28] Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein thrombosis. *Br J Haematol* 2015;168:459–60.
- [29] Ianotto JC, Chauveau A, Luque Paz D, Delluc A, Tromeur C, Couturier MA, et al. Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. *Thromb Haemost* 2015;115:225–6.
- [30] Verger E, Crassard I, Cassinat B, Bellucci S. Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm. *Thromb Res* 2015;136:839–40.